Mark N Lampert - Net Worth and Insider Trading
Mark N Lampert Net Worth
The estimated net worth of Mark N Lampert is at least $45 Million dollars as of 2024-05-14. Mark N Lampert is the Director, 10% Owner of Arena Pharmaceuticals Inc and owns about 452,021 shares of Arena Pharmaceuticals Inc (ARNA) stock worth over $45 Million. Details can be seen in Mark N Lampert's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark N Lampert has not made any transactions after 2003-10-17 and currently still holds the listed stock(s).
Transaction Summary of Mark N Lampert
Mark N Lampert Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Mark N Lampert owns 48 companies in total, including Five Prime Therapeutics Inc (FPRX) , Eledon Pharmaceuticals Inc (ELDN) , and XOMA Corp (XOMA) among others .
Click here to see the complete history of Mark N Lampert’s form 4 insider trades.
Insider Ownership Summary of Mark N Lampert
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| FPRX | Five Prime Therapeutics Inc | 2020-10-06 | 10 percent owner |
| ELDN | Eledon Pharmaceuticals Inc | 2020-10-01 | 10 percent owner |
| XOMA | XOMA Corp | 2017-02-10 | 10 percent owner |
 | | 2020-01-01 | 10 percent owner |
| | 2021-06-16 | other: See Explanation of Responses |
| | 2020-08-18 | 10 percent owner |
| | 2020-06-18 | 10 percent owner |
| | 2019-06-19 | 10 percent owner |
| | 2017-06-09 | 10 percent owner |
| | 2019-12-09 | 10 percent owner |
| | 2018-11-16 | 10 percent owner |
| | 2017-05-01 | 10 percent owner |
| | 2017-09-19 | 10 percent owner |
| | 2016-11-30 | 10 percent owner |
| | 2018-12-04 | 10 percent owner |
| | 2017-11-28 | 10 percent owner |
| | 2018-05-30 | 10 percent owner |
| | 2016-09-08 | 10 percent owner |
| | 2017-11-17 | 10 percent owner |
| | 2014-07-01 | 10 percent owner |
| | 2017-05-08 | 10 percent owner |
| | 2016-06-23 | director & 10 percent owner |
| | 2012-08-28 | 10 percent owner |
| | 2009-07-09 | 10 percent owner |
| | 2009-08-24 | 10 percent owner & other: Indirect Beneficial Owner |
| | 2014-03-21 | other: See Explanation of Responses |
| | 2011-10-05 | 10 percent owner |
| | 2013-05-01 | 10 percent owner |
| | 2011-10-07 | 10 percent owner |
| | 2009-12-22 | 10 percent owner |
| | 2009-12-18 | 10 percent owner |
| | 2009-10-21 | 10 percent owner |
| | 2009-07-30 | 10 percent owner |
| | 2009-05-15 | 10 percent owner & other: Group Member |
| | 2003-10-17 | director & 10 percent owner |
| | 2017-02-10 | 10 percent owner |
| | 2020-12-18 | 10 percent owner |
| | 2022-01-25 | 10 percent owner |
| | 2021-04-22 | other: See Explanation of Responses |
| | 2020-11-18 | 10 percent owner |
| | 2021-12-31 | 10 percent owner |
| | 2021-10-28 | 10 percent owner |
| | 2022-04-05 | director & 10 percent owner |
| | 2022-06-16 | 10 percent owner |
| | 2022-07-11 | 10 percent owner |
| | 2022-12-19 | 10 percent owner |
| | 2023-02-03 | 10 percent owner |
| | 2023-11-02 | 10 percent owner |
Mark N Lampert Latest Holdings Summary
Mark N Lampert currently owns a total of 1 stock. Mark N Lampert owns 452,021 shares of Arena Pharmaceuticals Inc (ARNA) as of October 17, 2003, with a value of $45 Million.
Latest Holdings of Mark N Lampert
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ARNA | Arena Pharmaceuticals Inc | 2003-10-17 | 452,021 | 99.99 | 45,197,580 |
Holding Weightings of Mark N Lampert
Mark N Lampert Form 4 Trading Tracker
According to the SEC Form 4 filings, Mark N Lampert has made a total of 0 transactions in Arena Pharmaceuticals Inc (ARNA) over the past 5 years. The most-recent trade in Arena Pharmaceuticals Inc is the sale of 291,100 shares on October 17, 2003, which brought Mark N Lampert around $22 Million.
Insider Trading History of Mark N Lampert
- 1
Mark N Lampert Trading Performance
Mark N Lampert Ownership Network
Mark N Lampert Owned Company Details
What does Five Prime Therapeutics Inc do?
Who are the key executives at Five Prime Therapeutics Inc?
Mark N Lampert is the 10 percent owner of Five Prime Therapeutics Inc. Other key executives at Five Prime Therapeutics Inc include 10 percent owner Biotechnology Value Fund L P , 10 percent owner Bvf Partners L P/il , and 10 percent owner Bvf Inc/il .
Five Prime Therapeutics Inc (FPRX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Five Prime Therapeutics Inc (FPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Five Prime Therapeutics Inc (FPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Five Prime Therapeutics Inc (FPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Five Prime Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Eledon Pharmaceuticals Inc do?
Who are the key executives at Eledon Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Eledon Pharmaceuticals Inc. Other key executives at Eledon Pharmaceuticals Inc include other: See Explanation of Responses Biotechnology Value Fund L P , director & See Remarks Steven Perrin , and director & Chief Executive Officer David-alexandre C Gros .
Eledon Pharmaceuticals Inc (ELDN) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Eledon Pharmaceuticals Inc (ELDN). Other recent insider transactions involving Eledon Pharmaceuticals Inc (ELDN) include a net purchase of 1,978,932 shares made by Biotechnology Value Fund L P , and a net purchase of 1,000 shares made by Steven Perrin .
In summary, during the past 3 months, insiders sold 0 shares of Eledon Pharmaceuticals Inc (ELDN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eledon Pharmaceuticals Inc (ELDN) were sold and 1,979,932 shares were bought by its insiders, resulting in a net purchase of 1,979,932 shares.
Eledon Pharmaceuticals Inc (ELDN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Eledon Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does XOMA Corp do?
Who are the key executives at XOMA Corp?
Mark N Lampert is the 10 percent owner of XOMA Corp. Other key executives at XOMA Corp include Chief Investment Officer Bradley Sitko , director & Interim CEO Owen Hughes , and other: See Explanation of Responses Biotechnology Value Fund L P .
XOMA Corp (XOMA) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in XOMA Corp (XOMA). Other recent insider transactions involving XOMA Corp (XOMA) include a net purchase of 9,100 shares made by Bradley Sitko , a net purchase of 5,500 shares made by Owen Hughes , and a net purchase of 22,249 shares made by Biotechnology Value Fund L P .
In summary, during the past 3 months, insiders sold 0 shares of XOMA Corp (XOMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Corp (XOMA) were sold and 36,849 shares were bought by its insiders, resulting in a net purchase of 36,849 shares.
XOMA Corp (XOMA)'s detailed insider trading history can be found in Insider Trading Tracker table.
XOMA Corp Insider Transactions
- Download to Excel(.xls)
What does Merus NV do?
Who are the key executives at Merus NV?
Mark N Lampert is the 10 percent owner of Merus NV. Other key executives at Merus NV include Chief Accounting Officer Harry Shuman , EVP & General Counsel Peter B. Silverman , and director & President & CEO & PFO Sven Ante Lundberg .
Merus NV (MRUS) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Merus NV (MRUS). Other recent insider transactions involving Merus NV (MRUS) include a net sale of 2,258 shares made by Harry Shuman , and a net sale of 22,386 shares made by Peter B. Silverman .
In summary, during the past 3 months, insiders sold 0 shares of Merus NV (MRUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 24,644 shares of Merus NV (MRUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 24,644 shares.
Merus NV (MRUS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Merus NV Insider Transactions
- Download to Excel(.xls)
What does Kymera Therapeutics Inc do?
Who are the key executives at Kymera Therapeutics Inc?
Mark N Lampert is the other: See Explanation of Responses of Kymera Therapeutics Inc. Other key executives at Kymera Therapeutics Inc include 10 percent owner Atlas Venture Fund X, L.p. , Chief Medical Officer Jared Gollob , and Chief Financial Officer Bruce N. Jacobs .
Kymera Therapeutics Inc (KYMR) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Kymera Therapeutics Inc (KYMR). Other recent insider transactions involving Kymera Therapeutics Inc (KYMR) include a net sale of 989,618 shares made by Bruce Booth , a net sale of 862,075 shares made by Atlas Venture Fund X, L.p. , and a net sale of 49,881 shares made by Jared Gollob .
In summary, during the past 3 months, insiders sold 846,935 shares of Kymera Therapeutics Inc (KYMR) in total and bought 0 shares, with a net sale of 846,935 shares. During the past 18 months, 1,925,173 shares of Kymera Therapeutics Inc (KYMR) were sold and 455,112 shares were bought by its insiders, resulting in a net sale of 1,470,061 shares.
Kymera Therapeutics Inc (KYMR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Kymera Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Principia Biopharma Inc do?
Who are the key executives at Principia Biopharma Inc?
Mark N Lampert is the 10 percent owner of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include director & President & CEO Martin Babler , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .
Principia Biopharma Inc (PRNB) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.
Principia Biopharma Inc Insider Transactions
- Download to Excel(.xls)
What does IDEAYA Biosciences Inc do?
Who are the key executives at IDEAYA Biosciences Inc?
Mark N Lampert is the 10 percent owner of IDEAYA Biosciences Inc. Other key executives at IDEAYA Biosciences Inc include director & President and CEO Yujiro S Hata , See Remarks Briseno Andres Ruiz , and VP & General Counsel Jason Throne .
IDEAYA Biosciences Inc (IDYA) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in IDEAYA Biosciences Inc (IDYA). Other recent insider transactions involving IDEAYA Biosciences Inc (IDYA) include a net sale of 38,970 shares made by Jason Throne , a net sale of 10,000 shares made by Briseno Andres Ruiz , and a net sale of 250,000 shares made by Yujiro S Hata .
In summary, during the past 3 months, insiders sold 0 shares of IDEAYA Biosciences Inc (IDYA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 311,470 shares of IDEAYA Biosciences Inc (IDYA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 311,470 shares.
IDEAYA Biosciences Inc (IDYA)'s detailed insider trading history can be found in Insider Trading Tracker table.
IDEAYA Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does Calithera Biosciences Inc do?
Who are the key executives at Calithera Biosciences Inc?
Mark N Lampert is the 10 percent owner of Calithera Biosciences Inc. Other key executives at Calithera Biosciences Inc include director & 10 percent owner Deepika Pakianathan , 10 percent owner Takeda Ventures, Inc. , and SR. VP & CLINICAL DEVELOPMENT Keith Orford .
Calithera Biosciences Inc (CALA) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Calithera Biosciences Inc (CALA). Other recent insider transactions involving Calithera Biosciences Inc (CALA) include a net sale of 121,333 shares made by Deepika Pakianathan ,
In summary, during the past 3 months, insiders sold 0 shares of Calithera Biosciences Inc (CALA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 121,333 shares of Calithera Biosciences Inc (CALA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 121,333 shares.
Calithera Biosciences Inc (CALA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Calithera Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does CTI BioPharma Corp do?
Who are the key executives at CTI BioPharma Corp?
Mark N Lampert is the 10 percent owner of CTI BioPharma Corp. Other key executives at CTI BioPharma Corp include EVP & Chief Commercial Officer James K Fong , director & President and CEO Adam R Craig , and EVP & Chief Financial Officer David Kirske .
CTI BioPharma Corp (CTIC) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in CTI BioPharma Corp (CTIC). Other recent insider transactions involving CTI BioPharma Corp (CTIC) include a net sale of 100,000 shares made by James K Fong , a net sale of 85,317 shares made by Adam R Craig , and a net sale of 54,042 shares made by David Kirske .
In summary, during the past 3 months, insiders sold 0 shares of CTI BioPharma Corp (CTIC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 239,359 shares of CTI BioPharma Corp (CTIC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 239,359 shares.
CTI BioPharma Corp (CTIC)'s detailed insider trading history can be found in Insider Trading Tracker table.
CTI BioPharma Corp Insider Transactions
- Download to Excel(.xls)
What does Cytokinetics Inc do?
Who are the key executives at Cytokinetics Inc?
Mark N Lampert is the 10 percent owner of Cytokinetics Inc. Other key executives at Cytokinetics Inc include SVP Research & Early Dev Fady Ibraham Malik , EVP & Corp. Development & CBO Robert I Blum , and VP & Chief Accounting Officer Robert Wong .
Cytokinetics Inc (CYTK) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Cytokinetics Inc (CYTK). Other recent insider transactions involving Cytokinetics Inc (CYTK) include a net sale of 312,500 shares made by Robert I Blum , a net sale of 147,222 shares made by Fady Ibraham Malik , and a net sale of 27,186 shares made by John T Henderson .
In summary, during the past 3 months, insiders sold 58,714 shares of Cytokinetics Inc (CYTK) in total and bought 0 shares, with a net sale of 58,714 shares. During the past 18 months, 532,166 shares of Cytokinetics Inc (CYTK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 532,166 shares.
Cytokinetics Inc (CYTK)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cytokinetics Inc Insider Transactions
- Download to Excel(.xls)
What does Pieris Pharmaceuticals Inc do?
Who are the key executives at Pieris Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Pieris Pharmaceuticals Inc. Other key executives at Pieris Pharmaceuticals Inc include 10 percent owner Bvf Gp Holdings Llc , 10 percent owner Bvf I Gp Llc , and other: See Explanation of Responses Bvf Ii Gp Llc .
Pieris Pharmaceuticals Inc (PIRS) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Pieris Pharmaceuticals Inc (PIRS). Other recent insider transactions involving Pieris Pharmaceuticals Inc (PIRS) include a net purchase of 10,000 shares made by Christopher P Kiritsy ,
In summary, during the past 3 months, insiders sold 0 shares of Pieris Pharmaceuticals Inc (PIRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pieris Pharmaceuticals Inc (PIRS) were sold and 125 shares were bought by its insiders, resulting in a net purchase of 125 shares.
Pieris Pharmaceuticals Inc (PIRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Pieris Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does GlycoMimetics Inc do?
Who are the key executives at GlycoMimetics Inc?
Mark N Lampert is the 10 percent owner of GlycoMimetics Inc. Other key executives at GlycoMimetics Inc include Chief Medical Officer Edwin Rock , CFO Brian M. Hahn , and SVP & Chief Commercial Officer Bruce S Johnson .
GlycoMimetics Inc (GLYC) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in GlycoMimetics Inc (GLYC). Other recent insider transactions involving GlycoMimetics Inc (GLYC) include a net purchase of 2,026,717 shares made by Invus Public Equities, L.p. , a net sale of 4,121,511 shares made by Scott D Sandell , and a net purchase of 375,403 shares made by Edwin Rock .
In summary, during the past 3 months, insiders sold 0 shares of GlycoMimetics Inc (GLYC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 4,125,211 shares of GlycoMimetics Inc (GLYC) were sold and 2,465,620 shares were bought by its insiders, resulting in a net sale of 1,659,591 shares.
GlycoMimetics Inc (GLYC)'s detailed insider trading history can be found in Insider Trading Tracker table.
GlycoMimetics Inc Insider Transactions
- Download to Excel(.xls)
What does Concert Pharmaceuticals Inc do?
Who are the key executives at Concert Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Concert Pharmaceuticals Inc. Other key executives at Concert Pharmaceuticals Inc include Chief Development Officer James V Cassella , CFO & PFO Marc A. Becker , and Chief Operating Officer Nancy Stuart .
Concert Pharmaceuticals Inc (CNCE) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Concert Pharmaceuticals Inc (CNCE). Other recent insider transactions involving Concert Pharmaceuticals Inc (CNCE) include a net sale of 16,093 shares made by Nancy Stuart , a net sale of 12,999 shares made by James V Cassella , and a net sale of 11,386 shares made by Jeffrey A Munsie .
In summary, during the past 3 months, insiders sold 0 shares of Concert Pharmaceuticals Inc (CNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 61,104 shares of Concert Pharmaceuticals Inc (CNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 61,104 shares.
Concert Pharmaceuticals Inc (CNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Concert Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Infinity Pharmaceuticals Inc do?
Who are the key executives at Infinity Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Infinity Pharmaceuticals Inc. Other key executives at Infinity Pharmaceuticals Inc include director & President & CEO Adelene Q Perkins , Chief Scientific Officer Stephane Peluso , and Chief Medical Officer Robert Jr. Ilaria .
Infinity Pharmaceuticals Inc (INFIQ) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Infinity Pharmaceuticals Inc (INFIQ). Other recent insider transactions involving Infinity Pharmaceuticals Inc (INFIQ) include a net sale of 410,196 shares made by Adelene Q Perkins ,
In summary, during the past 3 months, insiders sold 0 shares of Infinity Pharmaceuticals Inc (INFIQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 410,196 shares of Infinity Pharmaceuticals Inc (INFIQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 410,196 shares.
Infinity Pharmaceuticals Inc (INFIQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Infinity Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Immune Design Corp do?
Who are the key executives at Immune Design Corp?
Mark N Lampert is the 10 percent owner of Immune Design Corp. Other key executives at Immune Design Corp include 10 percent owner & other: General Partner Column Group Gp, Lp , 10 percent owner Column Group L P , and 10 percent owner & other: General Partner Ponoi Management, Llc .
Immune Design Corp (IMDZ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Immune Design Corp (IMDZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immune Design Corp (IMDZ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Immune Design Corp (IMDZ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Immune Design Corp Insider Transactions
- Download to Excel(.xls)
What does Syndax Pharmaceuticals Inc do?
Who are the key executives at Syndax Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Syndax Pharmaceuticals Inc. Other key executives at Syndax Pharmaceuticals Inc include director & Chief Executive Officer Briggs Morrison , Chief Financial Officer Keith A. Goldan , and President & Head of R&D Neil Gallagher .
Syndax Pharmaceuticals Inc (SNDX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Syndax Pharmaceuticals Inc (SNDX). Other recent insider transactions involving Syndax Pharmaceuticals Inc (SNDX) include a net sale of 369,983 shares made by Briggs Morrison , a net sale of 50,069 shares made by Peter Ordentlich , and a net sale of 83,000 shares made by William Meury .
In summary, during the past 3 months, insiders sold 0 shares of Syndax Pharmaceuticals Inc (SNDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 548,588 shares of Syndax Pharmaceuticals Inc (SNDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 548,588 shares.
Syndax Pharmaceuticals Inc (SNDX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Syndax Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Arqule Inc do?
Who are the key executives at Arqule Inc?
Mark N Lampert is the 10 percent owner of Arqule Inc. Other key executives at Arqule Inc include director & Chief Executive Officer Paolo Pucci , CFO and Treasurer Marc Schegerin , and See Remarks Brian Schwartz .
Arqule Inc (ARQL) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Arqule Inc (ARQL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arqule Inc (ARQL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Arqule Inc (ARQL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arqule Inc Insider Transactions
- Download to Excel(.xls)
What does Xenon Pharmaceuticals Inc do?
Who are the key executives at Xenon Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Xenon Pharmaceuticals Inc. Other key executives at Xenon Pharmaceuticals Inc include SVP Bus. & Corp. Development Sherrington Robin , director & PRESIDENT & CEO Ian Mortimer , and Chief Medical Officer Christopher John Kenney .
Xenon Pharmaceuticals Inc (XENE) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Xenon Pharmaceuticals Inc (XENE). Other recent insider transactions involving Xenon Pharmaceuticals Inc (XENE) include a net sale of 30,570 shares made by Gary Patou , a net sale of 150,477 shares made by Simon N. Pimstone , and a net sale of 31,655 shares made by Ian Mortimer .
In summary, during the past 3 months, insiders sold 22,229 shares of Xenon Pharmaceuticals Inc (XENE) in total and bought 0 shares, with a net sale of 22,229 shares. During the past 18 months, 260,631 shares of Xenon Pharmaceuticals Inc (XENE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 260,631 shares.
Xenon Pharmaceuticals Inc (XENE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Xenon Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Regulus Therapeutics Inc do?
Who are the key executives at Regulus Therapeutics Inc?
Mark N Lampert is the 10 percent owner of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Sr. VP & General Counsel Christopher Ray Aker , Chief Operating Officer Joseph P Hagan , and Chief Financial Officer Crispina Calsada .
Regulus Therapeutics Inc (RGLS) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Crispina Calsada , and a net sale of 5,468 shares made by Christopher Ray Aker .
In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc (RGLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 25,516 shares.
Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regulus Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Capstone Holding Corp do?
Who are the key executives at Capstone Holding Corp?
Mark N Lampert is the 10 percent owner of Capstone Holding Corp. Other key executives at Capstone Holding Corp include other: See Remarks Alimco Financial Corp , 10 percent owner Neil S Subin , and 10 percent owner Miller Lloyd I Iii .
Capstone Holding Corp (CAPS) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Capstone Holding Corp (CAPS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Capstone Holding Corp (CAPS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Capstone Holding Corp (CAPS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Capstone Holding Corp Insider Transactions
- Download to Excel(.xls)
What does Alpine Immune Sciences Inc do?
Who are the key executives at Alpine Immune Sciences Inc?
Mark N Lampert is the 10 percent owner of Alpine Immune Sciences Inc. Other key executives at Alpine Immune Sciences Inc include Senior VP and CFO James Paul Rickey , director & Executive Chairman and CEO Mitchell Gold , and director & 10 percent owner Xiangmin Cui .
Alpine Immune Sciences Inc (ALPN) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Alpine Immune Sciences Inc (ALPN). Other recent insider transactions involving Alpine Immune Sciences Inc (ALPN) include a net sale of 281,514 shares made by James Paul Rickey , a net sale of 213,302 shares made by Mitchell Gold , and a net sale of 1,546,347 shares made by Orbimed Advisors Llc .
In summary, during the past 3 months, insiders sold 19 shares of Alpine Immune Sciences Inc (ALPN) in total and bought 0 shares, with a net sale of 19 shares. During the past 18 months, 3,587,529 shares of Alpine Immune Sciences Inc (ALPN) were sold and 750,000 shares were bought by its insiders, resulting in a net sale of 2,837,529 shares.
Alpine Immune Sciences Inc (ALPN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Alpine Immune Sciences Inc Insider Transactions
- Download to Excel(.xls)
What does Cascadian Therapeutics Inc do?
Who are the key executives at Cascadian Therapeutics Inc?
Mark N Lampert is the director & 10 percent owner of Cascadian Therapeutics Inc. Other key executives at Cascadian Therapeutics Inc include 10 percent owner Nea Partners 15, L.p. , 10 percent owner New Enterprise Associates 15, L.p. , and 10 percent owner Jon Sakoda .
Cascadian Therapeutics Inc (CASC) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Cascadian Therapeutics Inc (CASC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cascadian Therapeutics Inc (CASC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Cascadian Therapeutics Inc (CASC)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cascadian Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does ChemoCentryx Inc do?
Who are the key executives at ChemoCentryx Inc?
Mark N Lampert is the 10 percent owner of ChemoCentryx Inc. Other key executives at ChemoCentryx Inc include SVP Finance & CFO & Secretary Susan M Kanaya , director & 10 percent owner & President & CEO and Director Thomas J. Schall , and SVP & Finance & Acctg Officer Yi Ching Yau .
ChemoCentryx Inc (CCXI) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of ChemoCentryx Inc (CCXI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ChemoCentryx Inc (CCXI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
ChemoCentryx Inc (CCXI)'s detailed insider trading history can be found in Insider Trading Tracker table.
ChemoCentryx Inc Insider Transactions
- Download to Excel(.xls)
What does Catalyst Biosciences Inc do?
Who are the key executives at Catalyst Biosciences Inc?
Mark N Lampert is the 10 percent owner of Catalyst Biosciences Inc. Other key executives at Catalyst Biosciences Inc include director & Chief Executive Officer Charles C Wu , director & President Songjiang Ma , and Chief Operating Officer Weiguo Ye .
Catalyst Biosciences Inc (CBIO) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Catalyst Biosciences Inc (CBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Catalyst Biosciences Inc (CBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Catalyst Biosciences Inc (CBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Catalyst Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does Ligand Pharmaceuticals Inc do?
Who are the key executives at Ligand Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner & other: Indirect Beneficial Owner of Ligand Pharmaceuticals Inc. Other key executives at Ligand Pharmaceuticals Inc include CHIEF LEGAL OFFICER & Andrew Reardon , Chief Financial Officer Octavio Espinoza , and CEO & President John L Higgins .
Ligand Pharmaceuticals Inc (LGND) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Ligand Pharmaceuticals Inc (LGND). Other recent insider transactions involving Ligand Pharmaceuticals Inc (LGND) include a net sale of 20,000 shares made by John L Higgins , a net sale of 10,852 shares made by John W Kozarich , and a net sale of 10,300 shares made by Andrew Reardon .
In summary, during the past 3 months, insiders sold 12,033 shares of Ligand Pharmaceuticals Inc (LGND) in total and bought 0 shares, with a net sale of 12,033 shares. During the past 18 months, 49,593 shares of Ligand Pharmaceuticals Inc (LGND) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 45,593 shares.
Ligand Pharmaceuticals Inc (LGND)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ligand Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Regado Biosciences Inc do?
Who are the key executives at Regado Biosciences Inc?
Mark N Lampert is the other: See Explanation of Responses of Regado Biosciences Inc. Other key executives at Regado Biosciences Inc include 10 percent owner Associates Domain , Chief Medical Officer Eric Lefebvre , and Chief Financial Officer Christopher Peetz .
Regado Biosciences Inc (RGDO) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Regado Biosciences Inc (RGDO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Regado Biosciences Inc (RGDO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Regado Biosciences Inc (RGDO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Regado Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does Palatin Technologies Inc do?
Who are the key executives at Palatin Technologies Inc?
Mark N Lampert is the 10 percent owner of Palatin Technologies Inc. Other key executives at Palatin Technologies Inc include Executive Vice President & CFO Stephen T Wills , director & President and CEO Carl Spana , and director & Exec. VP Research and Devel. Perry B Molinoff .
Palatin Technologies Inc (PTN) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Palatin Technologies Inc (PTN). Other recent insider transactions involving Palatin Technologies Inc (PTN) include a net sale of 5,700 shares made by Deveer Robert K Jr , a net purchase of 5,002 shares made by Stephen T Wills , and a net sale of 400 shares made by Alan W Dunton .
In summary, during the past 3 months, insiders sold 11,700 shares of Palatin Technologies Inc (PTN) in total and bought 6,000 shares, with a net sale of 5,700 shares. During the past 18 months, 17,098 shares of Palatin Technologies Inc (PTN) were sold and 26,000 shares were bought by its insiders, resulting in a net purchase of 8,902 shares.
Palatin Technologies Inc (PTN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Palatin Technologies Inc Insider Transactions
- Download to Excel(.xls)
What does Rigel Pharmaceuticals Inc do?
Who are the key executives at Rigel Pharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include EVP & Chief Financial Officer Dean L Schorno , Sr VP of Bus Dev and Com Ops Raul R Rodriguez , and EVP & Chief Commercial Officer David A Santos .
Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 73,234 shares made by Raul R Rodriguez , a net sale of 19,907 shares made by David A Santos , and a net sale of 18,017 shares made by Dean L Schorno .
In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 116,547 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 116,547 shares.
Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.
Rigel Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does Neurocrine Biosciences Inc do?
Who are the key executives at Neurocrine Biosciences Inc?
Mark N Lampert is the 10 percent owner of Neurocrine Biosciences Inc. Other key executives at Neurocrine Biosciences Inc include Chief Regulatory Officer Ingrid Delaet , Chief Commerical Officer Eric Benevich , and Chief Scientific Officer Jude Onyia .
Neurocrine Biosciences Inc (NBIX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Neurocrine Biosciences Inc (NBIX). Other recent insider transactions involving Neurocrine Biosciences Inc (NBIX) include a net sale of 247,240 shares made by Eric Benevich , a net sale of 150,252 shares made by Eiry Roberts , and a net sale of 61,528 shares made by Julie Cooke .
In summary, during the past 3 months, insiders sold 275,180 shares of Neurocrine Biosciences Inc (NBIX) in total and bought 0 shares, with a net sale of 275,180 shares. During the past 18 months, 1,153,642 shares of Neurocrine Biosciences Inc (NBIX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,153,642 shares.
Neurocrine Biosciences Inc (NBIX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Neurocrine Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does EPIRUS Biopharmaceuticals Inc do?
Who are the key executives at EPIRUS Biopharmaceuticals Inc?
Mark N Lampert is the 10 percent owner of EPIRUS Biopharmaceuticals Inc. Other key executives at EPIRUS Biopharmaceuticals Inc include Chief Business Officer Vincent Aurentz , Chief Financial Officer Thomas A. Shea , and director & Chief Executive Officer Amit Munshi .
EPIRUS Biopharmaceuticals Inc (EPRSQ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
EPIRUS Biopharmaceuticals Inc (EPRSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
EPIRUS Biopharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does MediciNova Inc do?
Who are the key executives at MediciNova Inc?
Mark N Lampert is the 10 percent owner of MediciNova Inc. Other key executives at MediciNova Inc include Chief Financial Officer Jason J Kruger , Chief Financial Officer Douglas Paulin , and Chief Scientific Officer Gaeta Federico C.a. .
MediciNova Inc (MNOV) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in MediciNova Inc (MNOV). Other recent insider transactions involving MediciNova Inc (MNOV) include a net sale of 12,646 shares made by Hideki Nagao ,
In summary, during the past 3 months, insiders sold 0 shares of MediciNova Inc (MNOV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 12,646 shares of MediciNova Inc (MNOV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 12,646 shares.
MediciNova Inc (MNOV)'s detailed insider trading history can be found in Insider Trading Tracker table.
MediciNova Inc Insider Transactions
- Download to Excel(.xls)
What does Neurobiological Technologies Inc do?
Who are the key executives at Neurobiological Technologies Inc?
Mark N Lampert is the 10 percent owner of Neurobiological Technologies Inc. Other key executives at Neurobiological Technologies Inc include 10 percent owner Ariel Warszawski , 10 percent owner Ryan Heslop , and 10 percent owner Firefly Management Co Gp, Llc .
Neurobiological Technologies Inc (NTII) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Neurobiological Technologies Inc (NTII) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Neurobiological Technologies Inc (NTII) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Neurobiological Technologies Inc (NTII)'s detailed insider trading history can be found in Insider Trading Tracker table.
Neurobiological Technologies Inc Insider Transactions
- Download to Excel(.xls)
What does Dynavax Technologies Corp do?
Who are the key executives at Dynavax Technologies Corp?
Mark N Lampert is the 10 percent owner of Dynavax Technologies Corp. Other key executives at Dynavax Technologies Corp include Principal Accounting Officer Justin Burgess , Chief Medical Officer and VP Robert Janssen , and Senior Vice President David F Novack .
Dynavax Technologies Corp (DVAX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Dynavax Technologies Corp (DVAX). Other recent insider transactions involving Dynavax Technologies Corp (DVAX) include a net sale of 186,515 shares made by David F Novack , a net sale of 46,327 shares made by Robert Janssen , and a net sale of 4,500,000 shares made by Hack Andrew A. F. .
In summary, during the past 3 months, insiders sold 20,526 shares of Dynavax Technologies Corp (DVAX) in total and bought 0 shares, with a net sale of 20,526 shares. During the past 18 months, 4,783,800 shares of Dynavax Technologies Corp (DVAX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,783,800 shares.
Dynavax Technologies Corp (DVAX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Dynavax Technologies Corp Insider Transactions
- Download to Excel(.xls)
What does Repligen Corp do?
Who are the key executives at Repligen Corp?
Mark N Lampert is the 10 percent owner & other: Group Member of Repligen Corp. Other key executives at Repligen Corp include Senior VP & R&D Ralf Kuriyel , director & Chief Executive Officer Anthony Hunt , and SVP & Global Operations & IT James Bylund .
Repligen Corp (RGEN) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Repligen Corp (RGEN). Other recent insider transactions involving Repligen Corp (RGEN) include a net sale of 1,850 shares made by Karen A Dawes , a net sale of 16,707 shares made by Anthony Hunt , and a net sale of 5,647 shares made by Jon Snodgres .
In summary, during the past 3 months, insiders sold 25,597 shares of Repligen Corp (RGEN) in total and bought 0 shares, with a net sale of 25,597 shares. During the past 18 months, 35,882 shares of Repligen Corp (RGEN) were sold and 1,500 shares were bought by its insiders, resulting in a net sale of 34,382 shares.
Repligen Corp (RGEN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Repligen Corp Insider Transactions
- Download to Excel(.xls)
What does Arena Pharmaceuticals Inc do?
Who are the key executives at Arena Pharmaceuticals Inc?
Mark N Lampert is the director & 10 percent owner of Arena Pharmaceuticals Inc. Other key executives at Arena Pharmaceuticals Inc include director & President and CEO Amit Munshi , EVP & Chief Commercial Officer Robert Lisicki , and Executive VP and CBO Vincent Aurentz .
Arena Pharmaceuticals Inc (ARNA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Arena Pharmaceuticals Inc (ARNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arena Pharmaceuticals Inc (ARNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Arena Pharmaceuticals Inc (ARNA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arena Pharmaceuticals Inc Insider Transactions
- Download to Excel(.xls)
What does XOMA Corp do?
Who are the key executives at XOMA Corp?
Mark N Lampert is the 10 percent owner of XOMA Corp. Other key executives at XOMA Corp include Chief Investment Officer Bradley Sitko , director & Interim CEO Owen Hughes , and 10 percent owner Bvf Ii Gp Llc .
XOMA Corp (XOMAO.PFD) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of XOMA Corp (XOMAO.PFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of XOMA Corp (XOMAO.PFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
XOMA Corp (XOMAO.PFD)'s detailed insider trading history can be found in Insider Trading Tracker table.
XOMA Corp Insider Transactions
- Download to Excel(.xls)
What does CytomX Therapeutics Inc do?
Who are the key executives at CytomX Therapeutics Inc?
Mark N Lampert is the 10 percent owner of CytomX Therapeutics Inc. Other key executives at CytomX Therapeutics Inc include SVP & Chief Scientific Officer Marcia Belvin , SVP & Finance and Accounting Christopher Ogden , and Chief Financial Officer Jeffrey B Landau .
CytomX Therapeutics Inc (CTMX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in CytomX Therapeutics Inc (CTMX). Other recent insider transactions involving CytomX Therapeutics Inc (CTMX) include a net sale of 55,496 shares made by Sean A. Mccarthy , a net sale of 16,868 shares made by Lloyd A Rowland , and a net sale of 16,235 shares made by Jeffrey B Landau .
In summary, during the past 3 months, insiders sold 47,819 shares of CytomX Therapeutics Inc (CTMX) in total and bought 0 shares, with a net sale of 47,819 shares. During the past 18 months, 121,072 shares of CytomX Therapeutics Inc (CTMX) were sold and 5,000 shares were bought by its insiders, resulting in a net sale of 116,072 shares.
CytomX Therapeutics Inc (CTMX)'s detailed insider trading history can be found in Insider Trading Tracker table.
CytomX Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Verastem Inc do?
Who are the key executives at Verastem Inc?
Mark N Lampert is the 10 percent owner of Verastem Inc. Other key executives at Verastem Inc include Vice President of Finance Daniel Calkins , Chief Operating Officer Dan Paterson , and Chief Financial Officer Robert E. Gagnon .
Verastem Inc (VSTM) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Verastem Inc (VSTM). Other recent insider transactions involving Verastem Inc (VSTM) include a net sale of 2,240 shares made by Daniel Calkins , a net sale of 39,211 shares made by Robert E. Gagnon , and a net sale of 41,587 shares made by Brian M Stuglik .
In summary, during the past 3 months, insiders sold 1,735 shares of Verastem Inc (VSTM) in total and bought 0 shares, with a net sale of 1,735 shares. During the past 18 months, 108,848 shares of Verastem Inc (VSTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 108,848 shares.
Verastem Inc (VSTM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Verastem Inc Insider Transactions
- Download to Excel(.xls)
What does Rain Oncology Inc do?
Who are the key executives at Rain Oncology Inc?
Mark N Lampert is the other: See Explanation of Responses of Rain Oncology Inc. Other key executives at Rain Oncology Inc include 10 percent owner Kevin C Tang , Principal Fin. & Acc. Officer Josephine Bruce , and 10 percent owner Tang Capital Management Llc .
Rain Oncology Inc (RAIN) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Rain Oncology Inc (RAIN). Other recent insider transactions involving Rain Oncology Inc (RAIN) include a net purchase of 1,198,445 shares made by Kevin C Tang , a net sale of 995,000 shares made by Boxer Capital, Llc , and a net purchase of 122,000 shares made by Franklin M Berger .
In summary, during the past 3 months, insiders sold 0 shares of Rain Oncology Inc (RAIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,168,973 shares of Rain Oncology Inc (RAIN) were sold and 1,494,418 shares were bought by its insiders, resulting in a net purchase of 325,445 shares.
Rain Oncology Inc (RAIN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Rain Oncology Inc Insider Transactions
- Download to Excel(.xls)
What does Olema Pharmaceuticals inc do?
Who are the key executives at Olema Pharmaceuticals inc?
Mark N Lampert is the 10 percent owner of Olema Pharmaceuticals inc. Other key executives at Olema Pharmaceuticals inc include director & Chief Technology Officer Cyrus Harmon , 10 percent owner Paradigm Biocapital Advisors Lp , and director & President and CEO Sean Bohen .
Olema Pharmaceuticals inc (OLMA) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Olema Pharmaceuticals inc (OLMA). Other recent insider transactions involving Olema Pharmaceuticals inc (OLMA) include a net sale of 283,181 shares made by Cyrus Harmon , a net sale of 44,370 shares made by David C. Myles , and a net sale of 8,742 shares made by Kovacs Shane William Charles .
In summary, during the past 3 months, insiders sold 65,000 shares of Olema Pharmaceuticals inc (OLMA) in total and bought 0 shares, with a net sale of 65,000 shares. During the past 18 months, 418,074 shares of Olema Pharmaceuticals inc (OLMA) were sold and 2,255,932 shares were bought by its insiders, resulting in a net purchase of 1,837,858 shares.
Olema Pharmaceuticals inc (OLMA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Olema Pharmaceuticals inc Insider Transactions
- Download to Excel(.xls)
What does Cullinan Therapeutics Inc do?
Who are the key executives at Cullinan Therapeutics Inc?
Mark N Lampert is the 10 percent owner of Cullinan Therapeutics Inc. Other key executives at Cullinan Therapeutics Inc include See Remarks Jennifer Michaelson , Acting Chief Business Officer Savill Corrine , and director & President and CEO Nadim Ahmed .
Cullinan Therapeutics Inc (CGEM) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Cullinan Therapeutics Inc (CGEM). Other recent insider transactions involving Cullinan Therapeutics Inc (CGEM) include a net sale of 83,555 shares made by Jennifer Michaelson , a net sale of 6,823 shares made by Jeffrey Trigilio , and a net sale of 3,809 shares made by Jeffrey Alan Jones .
In summary, during the past 3 months, insiders sold 63,606 shares of Cullinan Therapeutics Inc (CGEM) in total and bought 0 shares, with a net sale of 63,606 shares. During the past 18 months, 224,214 shares of Cullinan Therapeutics Inc (CGEM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 224,214 shares.
Cullinan Therapeutics Inc (CGEM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cullinan Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Repare Therapeutics Inc do?
Who are the key executives at Repare Therapeutics Inc?
Mark N Lampert is the 10 percent owner of Repare Therapeutics Inc. Other key executives at Repare Therapeutics Inc include EVP & Chief Medical Officer Maria Koehler , EVP & Chief Science Officer Michael Zinda , and EVP & Chief Financial Officer Steve Forte .
Repare Therapeutics Inc (RPTX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Repare Therapeutics Inc (RPTX). Other recent insider transactions involving Repare Therapeutics Inc (RPTX) include a net sale of 12,683 shares made by Michael Zinda , a net purchase of 2,011,010 shares made by Biotechnology Value Fund L P , and a net sale of 13,091 shares made by Lloyd Mitchell Segal .
In summary, during the past 3 months, insiders sold 21,690 shares of Repare Therapeutics Inc (RPTX) in total and bought 0 shares, with a net sale of 21,690 shares. During the past 18 months, 282,163 shares of Repare Therapeutics Inc (RPTX) were sold and 2,011,010 shares were bought by its insiders, resulting in a net purchase of 1,728,847 shares.
Repare Therapeutics Inc (RPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Repare Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does MoonLake Immunotherapeutics do?
Who are the key executives at MoonLake Immunotherapeutics?
Mark N Lampert is the director & 10 percent owner of MoonLake Immunotherapeutics. Other key executives at MoonLake Immunotherapeutics include director & Chief Executive Officer Santos Da Silva Jorge , Chief Scientific Officer Kristian Reich , and Chief Financial Officer Matthias Bodenstedt .
MoonLake Immunotherapeutics (MLTX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in MoonLake Immunotherapeutics (MLTX). Other recent insider transactions involving MoonLake Immunotherapeutics (MLTX) include a net purchase of 1,629,151 shares made by Bihua Chen , a net sale of 200,000 shares made by Kristian Reich , and a net sale of 184,740 shares made by Santos Da Silva Jorge .
In summary, during the past 3 months, insiders sold 384,740 shares of MoonLake Immunotherapeutics (MLTX) in total and bought 0 shares, with a net sale of 384,740 shares. During the past 18 months, 484,740 shares of MoonLake Immunotherapeutics (MLTX) were sold and 1,629,151 shares were bought by its insiders, resulting in a net purchase of 1,144,411 shares.
MoonLake Immunotherapeutics (MLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
MoonLake Immunotherapeutics Insider Transactions
- Download to Excel(.xls)
What does 4D Molecular Therapeutics Inc do?
Who are the key executives at 4D Molecular Therapeutics Inc?
Mark N Lampert is the 10 percent owner of 4D Molecular Therapeutics Inc. Other key executives at 4D Molecular Therapeutics Inc include Chief Legal and HR Officer Scott Bizily , director & Chief Executive Officer David Kirn , and Chief Medical Officer Robert Young Kim .
4D Molecular Therapeutics Inc (FDMT) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in 4D Molecular Therapeutics Inc (FDMT). Other recent insider transactions involving 4D Molecular Therapeutics Inc (FDMT) include a net sale of 39,387 shares made by Scott Bizily , a net sale of 340,847 shares made by David Kirn , and a net purchase of 310,000 shares made by Viking Global Investors Lp .
In summary, during the past 3 months, insiders sold 21,145 shares of 4D Molecular Therapeutics Inc (FDMT) in total and bought 0 shares, with a net sale of 21,145 shares. During the past 18 months, 949,786 shares of 4D Molecular Therapeutics Inc (FDMT) were sold and 850,000 shares were bought by its insiders, resulting in a net sale of 99,786 shares.
4D Molecular Therapeutics Inc (FDMT)'s detailed insider trading history can be found in Insider Trading Tracker table.
4D Molecular Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does ESSA Pharma Inc do?
Who are the key executives at ESSA Pharma Inc?
Mark N Lampert is the 10 percent owner of ESSA Pharma Inc. Other key executives at ESSA Pharma Inc include Chief Operating Officer Peter Virsik , director & Chief Executive Officer David Ross Parkinson , and Chief Financial Officer David S. Wood .
ESSA Pharma Inc (EPIX) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in ESSA Pharma Inc (EPIX). Other recent insider transactions involving ESSA Pharma Inc (EPIX) include a net sale of 78,475 shares made by Peter Virsik , a net purchase of 99,730 shares made by Franklin M Berger , and a net purchase of 33,657 shares made by David Ross Parkinson .
In summary, during the past 3 months, insiders sold 2,082 shares of ESSA Pharma Inc (EPIX) in total and bought 0 shares, with a net sale of 2,082 shares. During the past 18 months, 78,475 shares of ESSA Pharma Inc (EPIX) were sold and 133,387 shares were bought by its insiders, resulting in a net purchase of 54,912 shares.
ESSA Pharma Inc (EPIX)'s detailed insider trading history can be found in Insider Trading Tracker table.
ESSA Pharma Inc Insider Transactions
- Download to Excel(.xls)
What does Third Harmonic Bio Inc do?
Who are the key executives at Third Harmonic Bio Inc?
Mark N Lampert is the 10 percent owner of Third Harmonic Bio Inc. Other key executives at Third Harmonic Bio Inc include director & CEO Natalie C. Holles , Chief Administrative Officer Julie Person , and Chief Medical Officer Edward R. Conner .
Third Harmonic Bio Inc (THRD) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in Third Harmonic Bio Inc (THRD). Other recent insider transactions involving Third Harmonic Bio Inc (THRD) include a net sale of 33,780 shares made by Natalie C. Holles , a net sale of 13,970 shares made by Julie Person , and a net purchase of 214,063 shares made by Biotechnology Value Fund L P .
In summary, during the past 3 months, insiders sold 34,887 shares of Third Harmonic Bio Inc (THRD) in total and bought 0 shares, with a net sale of 34,887 shares. During the past 18 months, 52,540 shares of Third Harmonic Bio Inc (THRD) were sold and 214,063 shares were bought by its insiders, resulting in a net purchase of 161,523 shares.
Third Harmonic Bio Inc (THRD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Third Harmonic Bio Inc Insider Transactions
- Download to Excel(.xls)
What does Structure Therapeutics Inc do?
Who are the key executives at Structure Therapeutics Inc?
Mark N Lampert is the 10 percent owner of Structure Therapeutics Inc. Other key executives at Structure Therapeutics Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Gp Holdings Llc , and other: See Explanation of Responses Bvf Ii Gp Llc .
Structure Therapeutics Inc (GPCR) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Structure Therapeutics Inc (GPCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Structure Therapeutics Inc (GPCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Structure Therapeutics Inc (GPCR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Structure Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does POINT Biopharma Global Inc do?
Who are the key executives at POINT Biopharma Global Inc?
Mark N Lampert is the 10 percent owner of POINT Biopharma Global Inc. Other key executives at POINT Biopharma Global Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Partners L P/il , and 10 percent owner Bvf Gp Holdings Llc .
POINT Biopharma Global Inc (PNT) Insider Trades Summary
Over the past 18 months, Mark N Lampert made no insider transaction in POINT Biopharma Global Inc (PNT). Other recent insider transactions involving POINT Biopharma Global Inc (PNT) include a net sale of 17,161,278 shares made by Biotechnology Value Fund L P , a net purchase of 50,000 shares made by Allan C Silber , and a net purchase of 6,000 shares made by Jonathan R. Goodman .
In summary, during the past 3 months, insiders sold 0 shares of POINT Biopharma Global Inc (PNT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 17,161,278 shares of POINT Biopharma Global Inc (PNT) were sold and 70,830 shares were bought by its insiders, resulting in a net sale of 17,090,448 shares.
POINT Biopharma Global Inc (PNT)'s detailed insider trading history can be found in Insider Trading Tracker table.
POINT Biopharma Global Inc Insider Transactions
- Download to Excel(.xls)
Mark N Lampert Mailing Address
Above is the net worth, insider trading, and ownership report for Mark N Lampert. You might contact Mark N Lampert via mailing address: 1 Sansome St, 30th Fl, San Francisco Ca 94104.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
